<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138697</url>
  </required_header>
  <id_info>
    <org_study_id>KB97003 (A &amp; B)</org_study_id>
    <nct_id>NCT00138697</nct_id>
  </id_info>
  <brief_title>Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients</brief_title>
  <official_title>Kinetics, Efficacy and Safety of IVIG-L (Human Normal Intravenous Immunoglobulin for Intravenous Use) in Hypogammaglobulinemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin Plasma Products BV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanquin Plasma Products BV</source>
  <brief_summary>
    <textblock>
      The kinetics, efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L,&#xD;
      were studied in patients with hypogammaglobulinemia, who are regularly treated with&#xD;
      intravenous immunoglobulin substitution therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service&#xD;
      (FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of&#xD;
      intravenous immunoglobulin simplifies the infusion, eliminates possible mistakes in the&#xD;
      reconstitution with water for injections and reduces the space requirements in storage.&#xD;
&#xD;
      In addition to the donor selection and donor screening, several viral safety steps have been&#xD;
      included into the production process.&#xD;
&#xD;
      In this clinical trial, the efficacy and safety of IVIG-L in patients with&#xD;
      hypogammaglobulinemia, who are regularly treated with intravenous immunoglobulin substitution&#xD;
      therapy, will be studied. IVIG-L will also be studied in patients with chronic ITP (KB98001).&#xD;
      Data from both studies will be used for an application for marketing authorisation in Finland&#xD;
      and the Netherlands.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetics of IVIG-L in patients with hypogammaglobulinemia</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of IVIG-L in patients with hypogammaglobulinemia</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of IVIG-L in patients with hypogammaglobulinemia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the IgG trough level</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare dosage and treatment intervals</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Hypogammaglobulinemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIG-L</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary a- or hypogammaglobulinemia, particularly patients with X-linked&#xD;
             agammaglobulinemia (XLA) or Common Variable Immunodeficiency (CVID)&#xD;
&#xD;
          -  Used to replacement treatment with intravenous immunoglobulin with 2-4 week intervals&#xD;
&#xD;
          -  A stable clinical situation (no activity of any other disease; a stable immunoglobulin&#xD;
             dose)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  The patient/legally acceptable representative has signed the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any other investigational drug within 7 days before study entry or&#xD;
             previous enrolment in this study&#xD;
&#xD;
          -  Known allergic reactions to human plasma or plasma products&#xD;
&#xD;
          -  Have an ongoing progressive terminal disease, including HIV infection&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known insufficiency of coronary or cerebral circulation&#xD;
&#xD;
          -  Have renal insufficiency (plasma creatinine &gt; 115Âµmol/L)&#xD;
&#xD;
          -  Have an ongoing active disease causing general symptoms, e.g. chronic active&#xD;
             hepatitis, persistent enterovirus infection.&#xD;
&#xD;
          -  Have IgA deficiency, and anti-IgA antibodies have been detected&#xD;
&#xD;
          -  Active systemic lupus erythematosus (SLE)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J WM van der Meer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Centre Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leyenburg Hospital</name>
      <address>
        <city>The Hague</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>April 18, 2007</last_update_submitted>
  <last_update_submitted_qc>April 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2007</last_update_posted>
  <keyword>Agammaglobulinemia</keyword>
  <keyword>Hypogammaglobulinemia</keyword>
  <keyword>Immunoglobulins, Intravenous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

